Episode Player
Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials
The Lancet Oncology in conversation with
The Lancet Oncology in conversation with
Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials
Feb 03, 2025
The Lancet Group
Professor Ian Tannock (Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada) discusses his Policy Review on Common Sense Oncology principles for the design, analysis and reporting of phase 3 randomised clinical trials.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
